Core Points - Guizhou Bailing announced that its wholly-owned subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for clinical trials of Tangning Tongluo tablets for the treatment of type 2 diabetes [2] Company Summary - The clinical trial approval is significant for Bailing Yuxiu as it allows the company to advance its research and development efforts in diabetes treatment [2] - The approved clinical trial is expected to enhance the company's product portfolio and potentially increase its market share in the diabetes medication sector [2]

Core Viewpoint - Guizhou BaiLing's subsidiary BaiLing YuXiu has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for its drug, Tang Ning Tong Luo Pian, aimed at treating type 2 diabetes [1] Company Summary - Guizhou BaiLing's full subsidiary BaiLing YuXiu (Zhuhai) Pharmaceutical Co., Ltd. has been granted a Clinical Trial Approval Notice by NMPA [1] - The approved clinical trial is specifically for Tang Ning Tong Luo Pian, which is intended for use in type 2 diabetes treatment [1]

证券代码：002424 证券简称：贵州百灵 公告编号：2025-043 贵州百灵企业集团制药股份有限公司 关于全资子公司获得药物临床试验批准通知书的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2025 年 10 月 15 日，贵州百灵企业集团制药股份有限公司（以 下简称"公司"）全资子公司百灵毓秀（珠海）医药有限公司（以下 简称"百灵毓秀"）收到国家药品监督管理局（NMPA）核准签发的《药 物临床试验批准通知书》（通知书编号：2025LP02703），由百灵毓秀 申报的糖宁通络片临床试验申请获得批准，同意本品开展用于 2 型糖 尿病的临床试验。现将相关情况公告如下： 一、药物基本信息 药品名称：糖宁通络片 剂型：片剂 受理号：CXZL2500055 申请人：百灵毓秀（珠海）医药有限公司 适应症：用于 2 型糖尿病（湿热蕴结证）的适应症 结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 糖宁通络片临床试验申请符合药品注册的有关要求，在进一步完善临 床试验方案的基础上，同意本品开展用于 2 型糖尿病的临床试验。 本品曾于 2024 年获得用于 ...

贵州百灵(002424.SZ)公告，公司全资子公司百灵毓秀(珠海)医药有限公司(简称"百灵毓秀")收到国家药 品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由百灵毓秀申报的糖宁通络片临床试 验申请获得批准，同意本品开展用于2型糖尿病的临床试验。 ...

糖宁通络片是公司历经十多年研发的中药1.1类中药新药，2014年起就以医院制剂的形式在临床上使 用，积累了大量人用经验。2024年11月其治疗糖尿病视网膜病变的临床试验许可顺利获得国家药监局批 准，成为《中药注册管理专门规定》实施后，全国首个由医院制剂转化为新药，豁免Ⅰ、Ⅱ期临床试验 直接进入Ⅲ期临床的中药1.1类新药。本次治疗2型糖尿病临床试验许可的获批，也是在前期临床研究的 基础上获得的。作为纯中药单药对经治和初治2型糖尿病患者，通过充分调整人体内分泌机能，改善疾 病症状，逆转生化指标具有良好疗效，证明其药理作用。 格隆汇10月15日丨贵州百灵（维权）(002424.SZ)公布，全资子公司百灵毓秀（珠海）医药有限公司 （简称"百灵毓秀"）收到国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》，由 百灵毓秀申报的糖宁通络片临床试验申请获得批准，同意本品开展用于2型糖尿病的临床试验。 ...

转自：智通财经 【贵州百灵（维权）：全资子公司中药新药糖宁通络片获得2型糖尿病临床试验批准】智通财经10月15 日电，贵州百灵(002424.SZ)公告称，公司全资子公司百灵毓秀收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，同意糖宁通络片开展用于2型糖尿病的临床试验。此次获批将进一步丰 富公司在糖尿病治疗领域的产品线。糖宁通络片是公司历经十多年研发的中药1.1类中药新药，2014年 起就以医院制剂的形式在临床上使用，积累了大量人用经验。2024年11月其治疗糖尿病视网膜病变的临 床试验许可顺利获得国家药监局批准，成为《中药注册管理专门规定》实施后，全国首个由医院制剂转 化为新药，豁免Ⅰ、Ⅱ期临床试验直接进入Ⅲ期临床的中药1.1类新药。本次治疗2型糖尿病临床试验许 可的获批，也是在前期临床研究的基础上获得的。作为纯中药单药对经治和初治2型糖尿病患者，通过 充分调整人体内分泌机能，改善疾病症状，逆转生化指标具有良好疗效，证明其药理作用。 ...

贵州百灵（002424）(002424.SZ)公告，公司全资子公司百灵毓秀(珠海)医药有限公司(简称"百灵毓秀") 收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由百灵毓秀申报的糖宁通 络片临床试验申请获得批准，同意本品开展用于2型糖尿病的临床试验。 ...

Core Viewpoint - Guizhou Bailing's subsidiary, Bailing Yuxiu (Zhuhai) Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its drug, Tangning Tongluo Pian, aimed at treating type 2 diabetes [1] Group 1: Company Developments - The clinical trial application for Tangning Tongluo Pian, a Class 1 new traditional Chinese medicine developed over ten years, has been approved for use in type 2 diabetes [1] - The drug previously received clinical trial approval in 2024 for non-proliferative diabetic retinopathy [1] - The current clinical trial will explore the drug's efficacy for type 2 diabetes with damp-heat syndrome, indicating an expansion of its therapeutic indications [1] Group 2: Product Efficacy - Tangning Tongluo Pian is designed as a pure traditional Chinese medicine to treat both treated and untreated type 2 diabetes patients [1] - The drug aims to adjust the body's endocrine functions, improve disease symptoms, and reverse biochemical indicators, demonstrating promising efficacy [1]

证券日报网讯贵州百灵9月25日在互动平台回答投资者提问时表示，截至2025年9月19日，公司股东总户 数为83901户。 （文章来源：证券日报） ...

Core Viewpoint - Huachuang Yuxin (600155.SH) announced a lawsuit against Guizhou Bailing (002424.SZ) major shareholder Jiang Wei and his associates, involving a total amount of 1.761 billion yuan, which has attracted significant attention in the capital market [1] Company Overview - Guizhou Bailing, originally Anshun Pharmaceutical Factory, transformed from a loss-making entity to a leading national herbal medicine company under Jiang Wei's leadership, achieving a production value increase from 2 million to 10 million yuan in the same year [1] - The company went public in June 2010 and is known as the "first stock of herbal medicine," holding 167 approved drug licenses and 11% of the national herbal medicine licenses by 2018 [1] Financial Performance - Guizhou Bailing's stock price has declined significantly since 2017, with its market value shrinking to approximately 12 billion yuan by the end of 2018 [1] - From 2019 to 2021, Guizhou Bailing experienced a continuous decline in net profit, with decreases of 48.27%, 46.11%, and 18.49% respectively [2] - R&D investment dropped by 30% during the same period, contributing to a loss of market share and a more than 75% decline in net profit compared to its peak in 2018 [2] Debt and Legal Issues - The lawsuit stems from a 2019 financial support plan where Huachuang Securities provided 1.4 billion yuan to Jiang Wei, acquiring 11.54% equity in Guizhou Bailing [2] - Jiang Wei has reportedly paid approximately 2.1 billion yuan in interest and a total of 4.2 billion yuan in principal and interest by the second quarter of 2025 [3] - The lawsuit seeks repayment of the principal amount of 1.4 billion yuan and related costs due to insufficient stock value to recover the funds [3] Strategic Developments - Guizhou Bailing is expanding into international markets, establishing a company in Macau for overseas trade and registering products in various countries [4] - The company projects a revenue of 4 billion yuan and a net profit of 120 million yuan by 2025, aiming to enhance profitability through product integration [4] Market Performance - Since hitting a low in June 2024, Guizhou Bailing's stock has rebounded strongly, with an increase of nearly 90% from its previous low [5]